F2G, a UK-based clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections, has announced a US$100m financing round. The financing is…
UK: F2G announces US$100m financing to advance late-stage development and commercialization of Olorofim in the US
…
…






